The global imaging agents market size surpassed USD 10.18 billion in 2023 and is estimated to increase from USD 10.69 billion in 2024 to approximately USD 17.47 billion by 2034. It is projected to grow at a CAGR of 5.03% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Imaging Agents Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Imaging Agents Market Revenue and Volume Forecast, by Product, 2024-2034
8.1.1. Iodinated Contrast Media
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Gadolinium-based Contrast Media
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Microbubble Contrast Media
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Barium-based Contrast Media
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Imaging Agents Market Revenue and Volume Forecast, by Application, 2024-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Gastrointestinal
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Neurology
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Imaging Agents Market Revenue and Volume Forecast, by Modality, 2024-2034
10.1.1. X-Ray
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Computed Tomography (CT)
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Magnetic Resonance Imaging (MRI)
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Ultrasound
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
11.1. Imaging Agents Market Revenue and Volume Forecast, by End-use, 2024-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Ambulatory Surgical Centers
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Ambulatory Surgical Centers
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Volume Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Modality (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
13.1. Siemens Healthineers
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Canon Medical Systems Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. RadNet
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer Healthcare Pharmaceuticals
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Alliance Medical
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Lantheus Medical Imaging Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Guerbet Group
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lily
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Mindray and Hologic, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client